It’s been a big few weeks at FreMon Scientific. ZipThaw sales continue to reach more and more blood banks and clinics, and we’re excited to welcome two new leaders to the FMS team: CEO Jeff Lersch and COO Andrew Wolf.

As we welcome new team members, we also thank Dr. Farideh Bischoff for her dedication when she held the position.

CEO Jeff Lersch brings years of dynamic leadership and experience as FMS re-emerges from the Covid period. In his most recent position he directed sales and marketing of a medical device company to over $900m in sales. Jeff has worked with the Department of Defense, NIH, the Harvard Medical System, major hospital chains and purchasing organizations. FreMon Scientific customers in healthcare systems, cell and gene therapy, research, and veterinary care will be well served with Jeff at the helm.
Investors, vendors, regulators and colleagues welcome Jeff to FreMon Scientific.

We also welcome COO Andrew Wolf. Andrew’s consulted for us for several months and has 16+ years of experience in the medical device space. He helped steer massive growth for NuVasive, Accelus and others.

“I’m enthusiastic and honored to join the FreMon Scientific team. What has been built, in some of the most challenging of times, is incredible. I wanted to work with a company that has a disruptive technology that benefits patients, saves lives, helps to lower the overall cost of healthcare, and has the potential to grow rapidly,” Andrew shared in a recent investor note.